The Development Fund of the Executive Yuan is in its 30th year since establishment in 1973. In its early years, the Fund invested in petrochemical and semiconductor industries that were vital to national development plans. In recent years, the focus of its investment has shifted to the biotechnology and digital content industries; in line with Taiwan’s economic transformation and strategic development directions.
The Fund’s investment scope currently embraces semiconductors, optoelectronics, communications, financial services, precision machinery, transportation infrastructure, and biotechnology. The primary goal of the Fund is to serve as a catalyst for Taiwan’s economic development and to accomplish a multiplier effect in the courses of its investment process.
Economic development is the aspiration of all people in Taiwan. It is our expectation that the Development Fund can serve as a driver for Taiwan’s economy. Not only would the Fund propel forward our industries on the international stage, it would enable us to accomplish new grounds of industrial and economic achievements.
The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development…
Calvin Tsai and Jack Wu talk about their two-pronged international approach through pharmaceuticals and nutricare. The head of the nutricare business elaborates on the challenge of introducing milk products to…
A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not…
Charles Lin discusses the impact of investment in R&D on Lotus’s product line, and how this has shaped the competitive value of the company over the last decade, as well…
In Taiwan, GSK recently signed Memorandum of Understanding with the National Research Program of Biopharmaceuticals (NRPB), building on research partnerships in Taiwan that include a 2007 agreement with National Taiwan…
Dr. Wen, can you please explain the vision behind Mycenax, and the areas in which you are currently focused? Here at Mycenax, our vision is from bench to better life…
Dr. Karen Wen of Mycenax likened her company to a “kitchen.” Would you say the same of JHL? Racho Jordanov (RJ): We might…
The latest details regarding Article 46, a key piece of legislation attached to the second-generation health insurance reform, were announced this week. What are the key points to take away…
Phytohealth is a trailbalzer in the Taiwanese biotech industry: the first publically-listed biopharma company in the country, and the first company to receive NDA approval for a Botanical New Drug.…
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
Mr. Fang-Yue Lin was a Department of Health Minister before becoming Superintendent of TVGH just 7 short months ago. He shares with us his Insight to the reform of the…
Alex Ho has more than 15 years of significant pharmaceutical industry expertise, spanning across sales, marketing and product management in multinational companies. These companies include Novartis, Janssen, L’Oreal, GSK and…
See our Cookie Privacy Policy Here
